NCT04030533View on ClinicalTrials.gov

Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 29, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Healthy
Interventions
DRUG

Guselkumab (SC): Dose 1

Participants will receive a single dose of guselkumab (dose 1) subcutaneously.

DRUG

Guselkumab (SC): Dose 2

Participants will receive a single dose of guselkumab (dose 2) subcutaneously.

DRUG

Guselkumab (IV): Dose 1

Participants will receive a single IV infusion of guselkumab (dose 1).

DRUG

Guselkumab (IV): Dose 2

Participants will receive a single IV infusion of guselkumab (dose 2).

DRUG

Ustekinumab 6 mg/mL

Participants will receive a single IV infusion of ustekinumab 6 mg/mL solution.

Trial Locations (1)

100089

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04030533 - Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter